Trump Executive Order Directs Cannabis Rescheduling, Promising Tax Breaks for Businesses

President Donald Trump signed an executive order on December 18, 2025, directing the U.S. Attorney General to reclassify cannabis from a Schedule I to a Schedule III drug under the Controlled Substances Act (CSA), a move that promises significant tax relief and potential new investment for state-licensed cannabis businesses across the United States. This executive action, widely anticipated as a fundamental shift in federal drug policy, sets in motion a process that could alleviate a substantial financial burden for an industry currently operating under severe federal tax restrictions. The reclassification of cannabis from Schedule I, which includes substances like heroin and LSD, to Schedule III, alongside drugs such as Tylenol with codeine, represents the most significant shift in U.S. drug policy in decades, according to Tim Barash, chairman of the Coalition of Cannabis Scheduling Reform. The order also mandates White House officials to collaborate with Congress to expand access to cannabidiol (CBD) for some Americans. While the executive order itself does not legalize recreational cannabis use, nor does it immediately harmonize the patchwork of state and federal laws, it initiates a critical reevaluation of cannabis's federal status, primarily aimed at removing research barriers and aligning federal policy with the growing evidence of its medical applications and widespread state-level legalization. For small and mid-sized cannabis companies, the most immediate and impactful consequence of this directive is the prospect of substantial tax relief. Under its previous Schedule I classification, cannabis businesses have been subject to IRS Section 280E, a provision that prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. This has forced many legitimate, state-licensed cannabis operators to pay exorbitant effective tax rates, often upwards of 70-90%, by preventing them from deducting common operational costs such as rent, payroll, and marketing. In our experience at C&S Finance Group LLC, navigating Section 280E has been one of the most challenging aspects for our cannabis industry clients. It has severely hampered their profitability, reinvestment capabilities, and overall growth potential, forcing many to operate with extreme financial constraints. The shift to Schedule III, if finalized, would effectively exempt these businesses from 280E, allowing them to claim standard business deductions and bring their federal tax obligations more in line with other legitimate industries. This change is not merely a tax break; it's a fundamental restructuring of the financial landscape for cannabis enterprises, enabling greater capital retention and fostering a more sustainable business environment. The potential for significant tax savings is expected to drive new investment into the burgeoning cannabis sector. Tim Barash noted that this change will “empower the 425,000 people working in the U.S. cannabis industry and bring in new talent, capital, and awareness to an industry that has a positive impact on millions of people’s lives.” This influx of capital could fuel expansion, innovation, and job creation across the supply chain, from cultivation and processing to retail and ancillary services. Companies that have previously struggled to attract mainstream investors due to the federal illegality and punitive tax regime may find themselves in a more favorable position. Beyond the financial implications, the executive order also emphasizes increasing medical marijuana and cannabidiol research. The traditional understanding is that moving a substance from Schedule I to Schedule III would reduce bureaucratic hurdles and increase access for scientific study. President Trump specifically touted the goal of accelerating medical treatments and elevating evidence quality. However, the Congressional Research Service previously issued a report suggesting that an existing law might limit the actual impact of rescheduling on research efforts, indicating that the path to expanded research may still face legislative complexities. It is crucial for businesses and consumers to understand that the executive order does not instantly change the legal status of marijuana for recreational use, nor does it automatically lead to FDA-approved cannabis products. The directive initiates a formal rulemaking process, which includes a review by the Drug Enforcement Administration (DEA). This process typically involves public hearings where policymakers and the public can weigh in on the health implications of cannabis, before a final rule is published in the Federal Register. McGuireWoods, a law firm monitoring the situation, cautions that any final rule will not immediately harmonize state and federal systems, meaning state-level regulations and licensing requirements will remain critical. While President Trump has previously expressed concerns about the broader implications of legalized marijuana, particularly regarding potential health effects on the “brain and the mind,” this executive order marks a distinct shift in his administration’s approach, prioritizing medical research and regulatory alignment. His past statements reflected a more cautious stance, questioning the societal impacts of widespread legalization. The current directive, however, focuses on the medical and scientific aspects, signaling a pragmatic response to the evolving landscape of cannabis policy. We believe this is a critical turning point for the sector, and for businesses seeking to understand and leverage these complex changes, expert guidance in tax preparation and compliance is paramount. The ability to pivot quickly and understand the nuances of federal and state regulations will be key to capitalizing on the opportunities presented by these changes, while mitigating potential risks. C&S Finance Group LLC at csfinancegroup.com stands ready to assist companies in optimizing their financial strategies in this evolving regulatory environment. The coming months will be critical as federal agencies, including the DEA, HHS, NIH, and FDA, navigate the directives of the executive order. Businesses should closely monitor the rulemaking process, potential public hearings, and any subsequent Congressional engagement on statutory definitions and product parameters for hemp-derived cannabinoids. The ultimate scope and timeline of these changes will determine the full extent of their impact on the cannabis industry.